Effect of Cinnovex on Patients Suffering from Relapsing- Remitting Multiple Sclerosis

Abstract

Introduction: Multiple Sclerosis is an inflammatory (MS) disease of the central nervous system recognized as it demyelinates the brain and spinal cord. Much attempts have been taken to control and cure this decease among them Interferons have been widely used during recent two decades. Therefore, the present research aims to examine the effect of Cinnovex on patients have used it compared with the similar medicine Avonex. Methods: This clinical randomized trial was performed in order to test the effect of Cinnovex impact on clinical symptoms of patients suffering from relapsing- remitting multiple sclerosis (MS) at Poursina hospital in Rasht in 2007 for one year. Patients were divided into three 40 subject groups receiving Cinnovex, Avonex and a control group. The patients’ EDSS and disease relapse were measured at the beginning and at the end of the test. The data analyzed by SPSS 20. P < 0.05 was considered statistically significant. Results: There was no significant difference between EDSS of patients at the beginning of the study (1.95 ± 1.08) and EDSS of patients after one year experiment (1.97 ± 1.36). Also, based relapse (1.4 ± 0.7) decreased (P < 0.01) and a significant variance was found between EDSS of the patients received Cinnovex (1.97 ± 1.36) and the control group (3.06 ± 1.8) after one year (P < 0.001). In addition, Cinnovex and Avonex effects did not show a meaningful difference with each other. Conclusions: It seems that Cinnovex can prevent from relapse and progress of EDSS of relapsing- remitting MS patients.